🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Lilly to invest $4.5 billion on new facility to scale-up pipeline drug production

Published 10/02/2024, 07:38 AM
Updated 10/02/2024, 03:27 PM
© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.   REUTERS/Mike Blake/File Photo
LLY
-

(Reuters) -U.S. drugmaker Eli Lilly (NYSE:LLY) said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on developing new ways to manufacture its drugs and increasing production of experimental medicines used in clinical studies.

Lilly and Danish rival Novo Nordisk (NYSE:NVO) are market leaders for a class of weight-loss treatments known as GLP-1 agonists, which work by suppressing appetite. Some analysts expect this market will reach $150 billion by the early 2030s.

While its widely popular drugs Zepbound and Mounjaro have launched in the U.S., Lilly has several other obesity and neurological disease drugs in development.

The company has invested billions of dollars to increase production of tirzepatide, the active ingredient in Zepbound and Mounjaro, as the demand for these drugs has outpaced supply for most of this year.

Its obesity pipeline includes oral drug orforglipron and an injectable drug candidate retatrutide - both in late-stage studies.

The facility, Lilly Medicine Foundry, is expected to add 400 full-time jobs, including engineers, scientists, operations personnel and lab technicians. It will be located in Lebanon, Indiana and is expected to open in late 2027.

In an interview with CNBC, Lilly CEO David Ricks said the site could increase the company's output by 400%. Lilly said new technologies developed at the Medicine Foundry will be transferred to its other manufacturing sites for full-scale production.

© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020.   REUTERS/Mike Blake/File Photo

The facility is in addition to its previous manufacturing commitments in Lebanon, that include a $5.3 billion investment to manufacture active pharmaceutical ingredients for its latest diabetes and obesity medicines.

Lilly's total capital commitment in the United States is now over $23 billion since 2020, the drugmaker said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.